News

How does MDM2 inhibition work to treat MPNs?

Renowned experts Dr. Srdan Verstovsek and Dr. Jason Gotlib discuss MDM2 inhibition as an avenue for the treatment of MPNs and share information on an upcoming MDM2 clinical trial.

Promedior Presents Positive Data from a Phase 2 Study of PRM-151 in MF patients

Positive safety and early efficacy clinical data was proven during Promedior's Phase 2 study of PRM-151 in MF patients

Imago BioSciences to Expand Clinical Trial of IMG-7829 for MF Patients

"IMG-7289 has shown tremendous promise to be a meaningful treatment option for myelofibrosis patients, and these data support our clinical program," said Hugh Young Rienhoff, CEO of Imago BioSciences

Possible New Myelofibrosis Drug Gets Fast Tracked by the FDA

Sierra Oncology announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to momelotinib for the treatment of patients with intermediate/high-risk myelofibrosis.

MPN Updates from ASCO 2019

This yearly meeting brings together not only oncology professionals from all disciplines but also includes pharmaceutical companies, advocacy groups and more to discuss the latest updates in cancer research and treatment.

Researchers at Mount Sinai Investigate a Novel Class of Drugs for MPN Patients

Researchers in The Tisch Cancer Institute's Myeloproliferative Neoplasms (MPN) Program at Mount Sinai is investing a novel class of drugs for MPN patients.

MPNRF Celebrates 1st Annual Founder's Day

The MPN Research Foundation is celebrating our first annual Founder's Day in memory of Robert (Bob) Rosen, the person who started it all almost 20 years ago. Today, May 6th is particularly special as it was Bob's birthday, and we look forward to celebrating his legacy on this day for years to come.

Clinical Trial for AVID200 Doses First MF Patient

A TGF-Beta inhibitor - AVID 200 - is joining the race for new therapies for myeloproliferative neoplasms.

MPN Research Foundation's Patient Registry Featured in Cure Today

In an article published by CURE Magazine, Robyn M. Scherber, M.D., M.P.H, assistant professor of medicine in the Department of Hematology and Oncology at UT Health San Antonio MD Anderson Cancer Center, and co-author Michelle Woehrle, the executive director of the MPN Research Foundation sat down to discuss the newest findings from MPNRF's patient registry, myMPN.

Update on Promising MF Treatment, Momelotinib

Sierra Oncology is planning a new clinical trial for myelofibrosis patients called the MOMENTUM study.

MPNRF's Spring 2019 Newsletter has arrived!

Catch up on all the latest happenings in the global MPN community!

What Is This Rare Blood Cancer That Can Cause the Blood to Thicken?

Today on the CBS program, "The Doctors," Dr. Travis sits down with Matt, a polycythemia vera patient, and his physical Dr. Ellen Ritchie.

U.S. FDA Grants Priority Review for Fedratinib - New Drug Application in Myelofibrosis

In a press release published today, Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has granted a Priority Review for Fedratinib.

It's Rare Disease day AND a MATCH day!

The MPN Research Foundation is doing our part to advocate for the MPN patient population. The needs of patients are first and foremost in our minds when we choose what researchers to support, have conversations with the FDA, and raise awareness about these rare blood cancers.

Exciting Announcement from MPNRF!

This fall, in collaboration with MPN Advocacy & Education Int'l, The Leukemia & Lymphoma Society and UT Health San Antonio MD Anderson Cancer Center, MPNRF will be holding an externally led patient-focused drug development (PFDD) meeting with the U.S. Food and Drug Administration (FDA).